Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20478637 | 0.91 | PIN1 (0.51) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL1844443 | 0.87 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL9325738 | 0.87 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12662601 | 0.87 | CA1 (0.53) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5848207 | 0.86 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL20478894 | 0.86 | CA1 (0.52) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5848209 | 0.86 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5848210 | 0.86 | CA1 (0.55) | CA1CA2TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL3144553 | 0.82 | AADAT (0.44) | CA1CA2PIN1 | |
| SCHEMBL28069849 | 0.79 | PIN1 (0.54) | CA1CA2TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018154519-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| EP-1855548-A2 | MOLECULES COMPRISING LINKED ORGANIC MOIETIES AS FLAVOR MODIFIERS FOR COMESTIBLES COMPOSITIONS | Senomyx, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060257543-A1 | Molecules comprising linked organic moieties as flavor modifiers for comestible compositions | SENOMYX, INC. | 2006-11-16 | — | — | US | disclosed |
| WO-2006084184-A2 | MOLECULES COMPRISING LINKED ORGANIC MOIETIES AS FLAVOR MODIFIERS FOR COMESTIBLE COMPOSITIONS | SENOMYX, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244611-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | CA1 4864/4885CA2 1500/4885TAS1R3 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.